AN2 Therapeutics, Inc. (ANTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

AN2 Therapeutics, Inc. (ANTX) closed at USD 3.54 on 2026-10-14, a change of +174.4 % over the past year, with a market capitalization of USD 135.85M.

AN2 Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

AN2 Therapeutics, Inc. key figures

Previous close

USD 3.54 (2026-10-14)

1-year change

+174.4 %

Market cap

USD 135.85M

Enterprise value

USD 57.46M

P/E ratio (trailing)

-3.50

P/E ratio (forward)

-4.50

EPS (trailing)

-1.03

EPS (forward)

-0.80

PEG ratio

n/a

Price to book

1.72

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.71

Employees

21

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for AN2 Therapeutics, Inc. and compare it with other stocks.